This article will not provide step-by-step mixing instructions, reconstitution ratios, or personal dosing protocols for CJC-1295 or ipamorelin. These are unapproved compounds. Neither has standardised preparation or dosing guidelines validated by the clinical trial process. What can be reliably discussed is how these compounds have been investigated for route of administration and what the peer-reviewed literature does, and does not, say about non-injectable administration forms such as nasal sprays or oral tablets.
How to take CJC-1295 and Ipamorelin
A specific step-by-step „how-to” protocol cannot be responsibly provided. No published clinical studies have established a validated self-administration procedure for any of these compounds. Existing studies reflect controlled clinical settings, not a guide for home use. What the literature does confirm is the general investigated route of administration. The primary human trial for CJC-1295 administered the compound subcutaneously within clinical trial settings [1]. Pharmacokinetic studies of ipamorelin have utilised intravenous infusion in some studies [2] and nasal administration in others [3]. This reflects varied research designs, not a single agreed-upon consumer method.
No studies have tested CJC-1295 and ipamorelin when administered together as a combined regimen in humans. Therefore, there is no published data describing how both compounds would be administered jointly, in what order, or according to what combined schedule. Any specific combined „how-to” instructions circulating elsewhere do not originate from peer-reviewed clinical literature.
How to mix CJC-1295 and Ipamorelin
Reconstitution instructions go beyond what clinical trials for CJC-1295 and Ipamorelin have actually investigated or reported. This includes things like bacteriostatic water amount per milligram of peptide or how to combine two different peptides in one vial. Published studies used pre-prepared investigational drug. They did not detail a mixing procedure for self-study, let alone consumer replication. Providing specific reconstitution ratios, storage volumes or numbers like „how much bac water per X mg” would mean presenting numbers unsubstantiated by peer-reviewed data as settled fact. This would go against the aim of this series: to avoid making up details.
Reviews of this class of compounds have also noted something significant. The quality and consistency of products in the unregulated peptide supply chain is a real, documented problem. This means that even the starting material used for any reconstitution – its actual purity, concentration, or identity – cannot be assumed to match what is stated on the label [4]. For these reasons, this article does not provide mixing or reconstitution instructions.
CJC-1295 nasal spray and oral forms
There is significant, specific research into non-injectable routes of administration for this class of peptides. However, the details differ significantly between CJC-1295 and ipamorelin. Neither of these compounds is available as a nasal spray, oral tablet or capsule that has been established as clinically equivalent to the injection. For ipamorelin specifically, a pharmacokinetic study directly measured intranasal administration. It showed that bioavailability via this route is approximately 20%. This means that only about one-fifth of the dose reached the systemic circulation compared with an injection. This is significantly lower than some related growth hormone-releasing peptides tested in the same study, which showed bioavailability closer to 50–30 per cent [3]. Intranasal administration of ipamorelin is therefore pharmacologically feasible and has been investigated. However, it is measurably less effective than injection. This finding also stems from a controlled pharmacokinetic study, rather than from commercial intranasal spray products – these have not been validated on the basis of such studies.
For CJC-1295, the reviewed literature examined for this article did not include any study measuring nasal absorption or bioavailability specifically for this compound. Claims of „CJC-1295 nasal spray” being pharmacologically equivalent to injection are therefore not supported by the direct evidence identified herein.
Regarding oral forms – tablets, capsules, or pills – there is a well-established principle in peptide pharmacology worth knowing. Peptides like CJC-1295 and ipamorelin are broken down by digestive enzymes in the stomach and intestines before they can be absorbed intact. This is precisely why injectable or nasal routes have been investigated, rather than oral formulations.
There are separate studies on a structurally related but chemically distinct compound. NN703 is a small-molecule compound derived from the basic structure of ipamorelin, but specifically modified to survive oral administration. In animal studies, it demonstrated oral bioavailability in the range of 30% [5]. However, this concerned a different, specially designed molecule – not ipamorelin or CJC-1295 themselves. None of the published human studies identified in this review demonstrate that CJC-1295 or ipamorelin, in their standard peptide forms, are effectively absorbed when taken as oral tablets or capsules.
Limitations of current evidence
Research into the administration methods for this category of compounds is truly informative in places. Data on the nasal bioavailability of ipamorelin is a good example. However, they do not extend to validated mixing instructions, reconstitution protocols, co-administration schedules, or confirmed oral or nasal spray products specifically for CJC-1295.
Where related, but chemically distinct compounds, such as NN703, have been designed for oral use, these studies do not translate to CJC-1295 or standard Ipamorelin. Readers should exercise caution before assuming otherwise.
Disclaimer
This content is for educational and informational purposes only. It should not be interpreted as medical advice, preparation instructions, or a guide for self-administration. CJC-1295 and ipamorelin remain research compounds. Neither is approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. There is no validated protocol for reconstitution, mixing, or co-administration for these compounds in peer-reviewed literature. The quality and purity of products in the unregulated peptide supply chain also remain a documented issue.
References
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
- Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
- Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976
- Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: A critical review. Journal of Sports Medicine and Physical Fitness, 66(7), 880–885. https://doi.org/10.23736/S0022-4707.26.17773-1
- Hansen, B. S., Raun, K., Nielsen, K. K., Johansen, P. B., Hansen, T. K., Peschke, B., Lau, J., Andersen, P. H., & Ankersen, M. (1999). Pharmacological characterisation of a new oral GH secretagogue, NN703. European Journal of Endocrinology, 141(2), 180–189. https://doi.org/10.1530/eje.0.1410180